AndrewMartinBellingerMDPhD
Cardiology • Boston, MAPreventive Cardiology
Chief Scientific Officer, Verve Therapeutics; Co-founder, Lyndra Therapeutics Co-founder, Corner Therapeutics Cardiovascular Medicine, Brigham and Women's Hospital
Dr. Bellinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
75 Francis St
Division of Cardiology
Boston, MA 02115Phone+1 857-307-4000- Is this information wrong?
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2011 - 2015
University of California (San Francisco)Residency, Internal Medicine, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Certifications & Licensure
MA State Medical License 2011 - 2024
Publications & Presentations
PubMed
- 9 citationsA pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.Kanasty Rosemary, Susan Low, Nupura S. Bhise, Jung Yang, Erick Peeke, Marlene Schwarz, James R. Wright, Bennett Carter, Moorthy Saumya, Tyler Grant, Ben DeBenedictis, ...> ;Journal of Controlled Release. 2019 Mar 27
- 29 citationsA gastric resident drug delivery system for prolonged gram-level dosing of tuberculosis treatmentMalvika Verma, Karan Vishwanath, Feyisope Eweje, Niclas Roxhed, Tyler Grant, Castaneda Macy, Christoph Steiger, Hormoz Mazdiyasni, Taylor Bensel, Daniel Minahan, Vance...> ;Science Translational Medicine. 2019 Mar 13
- 21 citationsChanging the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form.Altreuter David, Ameya R. Kirtane, Tyler Grant, Cecilia Kruger, Giovanni Traverso, Andrew Bellinger> ;Expert Opinion on Drug Delivery. 2018 Nov 13
- Join now to see all
Press Mentions
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-Type and LDLR-Deficient Non-Human PrimatesMarch 3rd, 2023- Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsNovember 7th, 2022
- Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial HypercholesterolemiaSeptember 21st, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
